List of Excipients in Branded Drug EXALGO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT Rx USA LLC	EXALGO	hydromorphone hydrochloride	16590-942	BUTYLATED HYDROXYTOLUENE
STAT Rx USA LLC	EXALGO	hydromorphone hydrochloride	16590-942	CELLULOSE ACETATE
STAT Rx USA LLC	EXALGO	hydromorphone hydrochloride	16590-942	FERRIC OXIDE RED
STAT Rx USA LLC	EXALGO	hydromorphone hydrochloride	16590-942	FERROSOFERRIC OXIDE

Exalgo Excipient Strategy and Commercial Opportunities for Hydromorphone Extended-Release Tablets

Last updated: August 14, 2026

Exalgo is an extended-release hydromorphone hydrochloride tablet built around an osmotic delivery system. Its commercial value is concentrated in the drug-delivery architecture rather than in the active pharmaceutical ingredient, which is an established opioid with generic immediate-release alternatives. The strongest excipient opportunities involve osmotic cores, semipermeable membranes, controlled-release polymers, abuse-deterrent performance, and manufacturing platforms that can support generic or reformulated hydromorphone products.

Exalgo was approved by the FDA in 2010 under NDA 022272. The product uses a controlled-release tablet intended for once-daily administration in opioid-tolerant patients. Its formulation includes hydromorphone hydrochloride, an osmotic push layer, a semipermeable membrane and an external delivery orifice. The delivery system is designed to release drug at a controlled rate and to resist dose dumping when exposed to alcohol or mechanical manipulation.[1]

What excipients are used in Exalgo?

Exalgo uses excipients that perform distinct functions in the osmotic delivery system. The public FDA labeling identifies inactive ingredients including osmotic agents, tablet binders, lubricants, membrane-forming materials, plasticizers and coating components.[1]

Exalgo excipient functions

Formulation function	Representative excipient class	Commercial role
Osmotic driving force	Sodium chloride and related osmogens	Controls water influx and drug release
Drug-layer binding	Povidone and cellulose-based binders	Provides tablet strength and content uniformity
Push-layer expansion	Polymeric swelling agents	Drives drug suspension through the delivery orifice
Semipermeable membrane	Cellulose acetate	Controls water penetration and release rate
Membrane plasticization	Polyethylene glycol and related plasticizers	Improves membrane flexibility and coating integrity
Lubrication	Magnesium stearate	Supports tableting and ejection
Opacity and identification	Titanium dioxide and iron oxides	Provides color and visual differentiation
Film coating	Hypromellose and related coating materials	Protects the tablet and supports product identification

The commercial importance of these materials depends on whether they affect the release mechanism. Excipients in the core and membrane generally have higher strategic value than conventional lubricants or colorants because changes may alter release kinetics, bioequivalence, dose dumping behavior and regulatory comparability.

How does Exalgo’s osmotic delivery system work?

Exalgo uses an osmotic pump design. Water enters through a semipermeable membrane, hydrates the drug layer and push layer, and generates pressure that expels hydromorphone through a small orifice. The system is designed to provide controlled release over approximately 24 hours.[1]

The formulation architecture typically includes:

1. A hydromorphone drug layer.
2. A swelling or osmotic push layer.
3. A semipermeable cellulose acetate membrane.
4. A laser-drilled delivery orifice.
5. An external film coat for identification and handling.

This structure creates several formulation constraints. The membrane must have consistent permeability. The push layer must generate sufficient force across the intended storage and gastrointestinal conditions. The orifice must remain open and dimensionally consistent. The tablet must maintain mechanical integrity during manufacturing, packaging and transit.

These requirements create barriers to simple excipient substitution. A change in sodium chloride level, polymer viscosity, membrane weight gain, plasticizer concentration or orifice geometry can affect the complete release profile.

What excipients have the highest commercial value for Exalgo competitors?

The most valuable excipient categories are those that can support an equivalent or improved controlled-release system while reducing manufacturing cost or improving regulatory performance.

Osmotic agents

Sodium chloride is a central osmogen in osmotic delivery systems. Other salts and water-soluble osmotic materials may be evaluated, but substitution can change osmotic pressure, water uptake, drug-layer hydration and release rate.

Commercial opportunities include:

• Lower-cost osmogen grades with tighter particle-size control.
• Excipient blends that reduce segregation during bilayer compression.
• Materials with improved compaction and lower hygroscopicity.
• Osmogen systems that maintain release performance across temperature and humidity conditions.
• Custom grades designed for high-dose opioid tablets.

A supplier that can provide pharmaceutical-grade sodium chloride or alternative osmotic materials with narrow particle-size distribution may compete on process consistency rather than simply price.

Push-layer polymers

The push layer is one of the most technically sensitive portions of an osmotic tablet. It must swell predictably and generate sufficient force without damaging the membrane or causing premature release.

Relevant materials include high-viscosity cellulose derivatives, polyethylene oxide polymers and other swellable hydrophilic polymers. Commercial differentiation may come from:

• Controlled molecular-weight distribution.
• Low peroxide and low endotoxin levels.
• Consistent swelling behavior.
• Better compatibility with direct compression.
• Reduced sensitivity to compression force.
• Improved stability under high humidity.

Polyethylene oxide grades used in osmotic systems have particular strategic value because molecular weight can influence swelling pressure, gel strength and release kinetics. A supplier with validated high-molecular-weight polymer grades may access both generic hydromorphone and broader osmotic oral-solid-dose programs.

Semipermeable membrane materials

Cellulose acetate is the principal membrane-forming material identified in Exalgo’s labeling.[1] The membrane controls the rate at which water enters the tablet. Coating weight, polymer substitution, solvent system, plasticizer concentration and drying conditions can materially affect performance.

Commercial opportunities include:

• Cellulose acetate grades optimized for aqueous or organic coating systems.
• Ready-to-use membrane dispersions.
• Lower-solvent coating processes.
• Membranes with improved crack resistance.
• Coating systems that provide tighter release specifications.
• Process analytical technology for membrane weight gain and uniformity.

Membrane suppliers can also compete through manufacturing support. A formulation may be technically viable but commercially unattractive if the coating process requires long cycle times, high solvent consumption or narrow environmental controls.

Plasticizers and pore-forming components

Plasticizers improve membrane flexibility and reduce cracking. Polyethylene glycol and related materials can also influence membrane permeability. Pore-forming agents may be used in alternative osmotic designs to accelerate water entry.

The main commercial requirement is reproducibility. A plasticizer that produces a robust membrane at laboratory scale may perform differently in commercial coating equipment because of differences in atomization, drying rate and bed temperature.

What formulation patents protect Exalgo’s delivery technology?

Exalgo’s protection has historically involved a combination of drug-specific patent claims and broader controlled-release technology. The relevant intellectual-property categories include:

• Hydromorphone extended-release compositions.
• Osmotic push-pull tablets.
• Semipermeable membrane systems.
• Controlled-release opioid dosage forms.
• Abuse-deterrent or tamper-resistant characteristics.
• Methods of treating pain in opioid-tolerant patients.
• Manufacturing processes for bilayer compression and membrane coating.

The core technology is associated with ALZA Corporation’s osmotic delivery platform, which was later incorporated into Johnson & Johnson’s pharmaceutical businesses. The commercial product was marketed by Neuromed Pharmaceuticals and later by Zogenix.[2][3]

Patent analysis should separate platform patents from Exalgo-specific patents. Older osmotic pump patents may have expired or become less commercially relevant, while later product-specific patents may have covered the hydromorphone formulation, dosage strength, release profile or method of use.

Why excipient changes can create patent risk

A generic or follow-on manufacturer may avoid a composition claim by changing the excipient system. That strategy can fail if the relevant claims cover functional characteristics, such as:

• A specified release profile.
• A multilayer osmotic configuration.
• A membrane with defined permeability.
• A drug layer and push layer arranged in a particular structure.
• A method of administering hydromorphone once daily.
• Resistance to alcohol-induced dose dumping.

An excipient substitution is therefore not automatically a freedom-to-operate solution. The legal analysis must compare the proposed formulation with issued claims, prosecution history and any Orange Book-listed patents.

What is the FDA regulatory status of Exalgo?

The FDA approved Exalgo as an extended-release hydromorphone hydrochloride tablet under NDA 022272 on March 1, 2010.[1] The product was indicated for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment in opioid-tolerant patients.

Exalgo carries the regulatory characteristics of an extended-release opioid:

• Restricted patient population.
• High risk of respiratory depression and overdose.
• Requirements for opioid-tolerant use.
• Strong controls on crushing, chewing and dissolving.
• Risk-management obligations associated with extended-release and long-acting opioids.
• Manufacturing controls intended to maintain the release profile.

The labeling warns that crushing, chewing or dissolving the tablets can result in rapid release of hydromorphone and may cause overdose or death.[1] This warning makes mechanical integrity and abuse-deterrent behavior commercially relevant even where a follow-on product is not required to carry an abuse-deterrent labeling claim.

What is the Orange Book status of Exalgo?

The Orange Book is the principal source for FDA-listed patents, exclusivity and approved therapeutic-equivalence information. Exalgo’s regulatory assessment should include:

• NDA 022272.
• Approved strengths and dosage forms.
• Listed patents and expiration dates.
• Any pediatric exclusivity adjustment.
• Approved ANDAs for hydromorphone extended-release tablets.
• Therapeutic-equivalence codes.
• Current marketing status.

An Orange Book listing does not establish that every formulation feature is protected. The listed patents may cover the drug product, method of use or a specific formulation. Some technology used in the product may be unlisted, expired or protected only through trade secrets.

For commercial planning, the key question is whether a proposed generic can obtain approval through an ANDA and certify against listed patents under Paragraph I, II, III or IV. A Paragraph IV certification can create patent litigation risk and a potential 30-month stay of approval under the Hatch-Waxman framework.[4]

When did Exalgo lose exclusivity and when can generic entry occur?

Exalgo’s five-year new chemical entity exclusivity began with its 2010 approval and generally ended in 2015, subject to statutory adjustments and any applicable patent barriers.[1][4] Generic entry depends on patent certifications, litigation, FDA approval and commercial decisions by ANDA sponsors.

The key timeline is:

Event	Timing
FDA approval of Exalgo	March 1, 2010
Likely end of five-year NCE exclusivity	2015
Potential ANDA filing window	After applicable NCE exclusivity restrictions
Generic approval	Dependent on patent certifications and FDA review
Commercial launch	Dependent on approval, litigation and market economics

A generic hydromorphone ER product faces greater development complexity than a conventional immediate-release tablet. The ANDA sponsor must demonstrate pharmaceutical equivalence and bioequivalence, including an acceptable release profile for a complex modified-release dosage form.

How strong is the Exalgo patent estate?

The patent estate is strongest where it combines product-specific claims with difficult-to-design-around delivery features. The most defensible technical features are likely to include the multilayer osmotic architecture, membrane-controlled delivery, push-layer behavior and defined hydromorphone release characteristics.

The estate is weaker where protection depends only on:

• Conventional hydromorphone use.
• Broad opioid treatment claims.
• Basic tablet excipients.
• Expired osmotic technology.
• Noncritical colorants or coating materials.

A practical strength assessment should score each patent against five factors:

Factor	High-strength indicator
Claim scope	Covers product structure or release function
Remaining term	Material life remains after regulatory approval
Design-around difficulty	Requires a different delivery platform
Validity position	Supported by substantial prosecution history
Market relevance	Covers commercially important strengths or indications

The excipient supplier’s own patent estate can add value by protecting polymer grades, membrane compositions, coating methods, osmotic excipient combinations or process controls.

What commercial opportunities exist in Exalgo-related excipients?

The commercial opportunity is broader than supplying ingredients to an Exalgo generic. The same excipient technologies can support other extended-release opioids, ADHD products, cardiovascular medicines and gastrointestinal delivery systems.

Opportunity 1: Generic hydromorphone ER platforms

A supplier can develop a formulation package containing:

• A qualified osmogen.
• A high-performance push-layer polymer.
• A cellulose acetate membrane system.
• A plasticizer and pore-former package.
• Compression and coating process parameters.
• Analytical methods for release testing.

This package can reduce development time for ANDA sponsors and smaller pharmaceutical companies.

Opportunity 2: Abuse-deterrent opioid formulations

FDA guidance identifies physical and chemical barriers, agonist-antagonist combinations, aversion systems and delivery-system approaches as potential abuse-deterrent technologies.[5] Osmotic tablets can contribute to physical resistance and controlled release, although abuse-deterrent claims require product-specific evidence.

Excipient opportunities include:

• Higher-strength matrix systems.
• Polymers that resist crushing.
• Gels that limit syringeability after manipulation.
• Coatings that resist alcohol extraction.
• Materials that maintain release control after mechanical stress.

Opportunity 3: Improved manufacturability

Manufacturing improvements may be more commercially valuable than new excipient chemistry. Potential products include:

• Direct-compression excipient blends.
• Low-dust osmotic cores.
• Ready-to-coat membrane dispersions.
• Process controls for bilayer alignment.
• Excipient systems compatible with continuous manufacturing.
• Coating formulations that reduce solvent use and drying time.

Opportunity 4: Reformulated hydromorphone products

A sponsor could pursue a differentiated product using a multiparticulate capsule, matrix tablet, sprinkle formulation or alternative abuse-deterrent platform. Each approach would carry different regulatory and intellectual-property implications.

The highest-value reformulation would need to offer a clear clinical or commercial advantage, such as:

• Lower pill burden.
• More consistent overnight analgesia.
• Improved swallowing.
• Reduced dose dumping.
• Better tamper resistance.
• A lower manufacturing cost.

How does Exalgo compare with conventional hydromorphone products?

Attribute	Exalgo	Immediate-release hydromorphone
Active ingredient	Hydromorphone hydrochloride	Hydromorphone hydrochloride
Release	Extended, once daily	Immediate
Primary technology	Osmotic delivery system	Conventional tablet or capsule
Patient population	Opioid-tolerant patients requiring continuous treatment	Acute or breakthrough pain
Excipient value	High in membrane, push layer and osmogen	Lower, mainly tableting and disintegration
Development complexity	High	Moderate to low
Generic substitution risk	Constrained by modified-release performance	More exposed to commodity competition
Manufacturing barrier	Bilayer compression and controlled coating	Conventional solid-dose manufacturing

Exalgo’s excipient strategy creates a higher technical barrier than an immediate-release hydromorphone product. That barrier can support premium formulation services, but the market is limited by opioid prescribing restrictions, payer controls and the relatively narrow patient population.

What generic entry risks exist for Exalgo?

Generic-entry risk is driven by four factors:

1. The number of approved or pending ANDAs.
2. The remaining term of listed patents.
3. The complexity of demonstrating bioequivalence.
4. The commercial attractiveness of the market.

A generic sponsor may pursue one of three strategies:

• Replicate the osmotic architecture closely.
• Design around the patented structure with another extended-release technology.
• Challenge listed patents through Paragraph IV certification.

A close replication may simplify clinical and pharmacokinetic development but increase patent exposure. A design-around may reduce infringement risk but increase formulation and bioequivalence risk. The commercial outcome depends on whether the generic can achieve acceptable release similarity without reproducing protected structural features.

What licensing opportunities are available for Exalgo-related technology?

Potential licensing targets include:

• Osmotic pump patents.
• High-molecular-weight polymer technology.
• Abuse-deterrent excipient systems.
• Bilayer tablet manufacturing platforms.
• Membrane coating processes.
• Hydromorphone formulation know-how.
• Generic development packages.

The most attractive licensing structure would link an excipient platform to development services, regulatory documentation and supply rights. A simple material-supply agreement may produce lower value than a formulation partnership that includes process transfer, analytical methods and regulatory support.

Licensing diligence should examine ownership of ALZA-derived technology, patent expiration, field-of-use restrictions, manufacturing know-how, supplier qualification and rights to improvements.

Key Takeaways

• Exalgo is a once-daily extended-release hydromorphone tablet based on osmotic pump technology.
• The highest-value excipients are osmotic agents, push-layer polymers, cellulose acetate membrane materials and plasticizers.
• Conventional lubricants and colorants have limited strategic differentiation.
• The formulation’s main barrier is the integrated delivery system, not hydromorphone itself.
• Generic developers must manage both Paragraph IV patent risk and complex modified-release bioequivalence requirements.
• Commercial opportunities exist in excipient packages, abuse-deterrent delivery systems, manufacturing improvements and reformulated hydromorphone products.
• The strongest supplier proposition combines excipient performance with process development, analytical methods and regulatory support.
• Current Orange Book listings, ANDA approvals and patent status should be assessed directly against the proposed formulation and launch date.

FAQs

Can sodium chloride be replaced in an Exalgo-style osmotic tablet?

Potentially, but the substitute must reproduce the required osmotic pressure, hydration behavior and release profile. A change can affect bioequivalence and may implicate formulation claims.

Which polymer is most important in an Exalgo generic?

The push-layer polymer is often the most technically important because its swelling pressure and gel behavior influence drug delivery. Molecular weight, particle size and moisture content can materially affect performance.

Does an abuse-deterrent excipient automatically support abuse-deterrent labeling?

No. Abuse-deterrent labeling depends on product-specific evidence under FDA standards. A formulation component alone does not establish a labeling claim.[5]

Is Exalgo vulnerable to a matrix-tablet design around?

Possibly, but a matrix formulation may create different release, food-effect and dose-dumping challenges. It may also require a separate regulatory strategy and may not avoid every method-of-use or functional patent claim.

Are Exalgo excipients useful for non-opioid products?

Yes. Osmotic delivery materials can support extended-release products in therapeutic areas including cardiovascular disease, central nervous system disorders, diabetes and gastrointestinal disease.

References

1. U.S. Food and Drug Administration. (2010). Exalgo (hydromorphone hydrochloride) extended-release tablets prescribing information. NDA 022272.

2. Johnson & Johnson. (2010). Annual report 2010. Johnson & Johnson.

3. Zogenix, Inc. (2012). Exalgo product and corporate filings. U.S. Securities and Exchange Commission.

4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Food and Drug Administration. (2015). Abuse-deterrent opioids: Evaluation and labeling guidance for industry. FDA.